Squarepoint
KRTX

Squarepoint’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Squarepoint’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,328
Closed -$420K – 4775
2023
Q4 		$420K Sell
1,328
-9,632
-88% -$1.87M ﹤0.01% 3139
2023
Q3 		$1.85M Buy
10,960
+6,469
+144% +$1.22M ﹤0.01% 1879
2023
Q2 		$974K Buy
+4,491
New +$962K ﹤0.01% 2179
2023
Q1 		– Sell
-16,465
Closed -$3.24M – 3957
2022
Q4 		$3.24M Sell
16,465
-6,411
-28% -$1.37M 0.01% 1074
2022
Q3 		$5.14M Buy
+22,876
New +$4.63M 0.03% 739
2021
Q3 		– Sell
-2,729
Closed -$311K – 3581
2021
Q2 		$311K Buy
+2,729
New +$319K ﹤0.01% 2502
2021
Q1 		– Sell
-14,982
Closed -$1.52M – 3750
2020
Q4 		$1.52M Sell
14,982
-7,702
-34% -$714K 0.01% 1074
2020
Q3 		$1.75M Sell
22,684
-35,814
-61% -$3.05M 0.02% 696
2020
Q2 		$6.52M Buy
58,498
+51,818
+776% +$4.51M 0.11% 271
2020
Q1 		$481K Buy
+6,680
New +$571K 0.01% 1067

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Squarepoint's KRTX Position: Q1 2024 in Review

Squarepoint sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 1,328 shares — an estimated $420K sold.

Squarepoint first reported a position in KRTX in Q1 2020 and held it in 10 quarters. The position peaked at $6.52M in Q2 2020. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Squarepoint reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Squarepoint sold 1,328 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $420K.
  • Squarepoint first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2020 and held it in 10 quarters.
  • Squarepoint's Karuna Therapeutics, Inc. Common Stock position peaked at $6.52M in Q2 2020.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Squarepoint's 13F filing for Q1 2024, filed 15 May 2024.